What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Surgery
Luigi Bolondi mainly investigates Internal medicine, Hepatocellular carcinoma, Cirrhosis, Gastroenterology and Radiology.
His research in Internal medicine intersects with topics in Oncology and Cardiology.
His work carried out in the field of Hepatocellular carcinoma brings together such families of science as Carcinoma, Surgery and Liver transplantation.
His Cirrhosis research is multidisciplinary, incorporating perspectives in Splanchnic, Percutaneous ethanol injection and Pathology.
His studies in Gastroenterology integrate themes in fields like Superior mesenteric artery, Resection, Retrospective cohort study and Risk factor.
In his research, Recurrent Hepatocellular Carcinoma, Performance status and Interim analysis is intimately related to Hazard ratio, which falls under the overarching field of Sorafenib.
His most cited work include:
- Sorafenib in Advanced Hepatocellular Carcinoma (7596 citations)
- Hepatocellular Carcinoma and Cirrhosis in 746 Patients: Long-Term Results of Percutaneous Ethanol Injection (830 citations)
- Cyclin G1 Is a Target of miR-122a, a MicroRNA Frequently Down-regulated in Human Hepatocellular Carcinoma (700 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Internal medicine, Hepatocellular carcinoma, Radiology, Cirrhosis and Gastroenterology.
His Internal medicine research integrates issues from Surgery, Oncology and Cardiology.
His Hepatocellular carcinoma study combines topics in areas such as Carcinoma and Pathology.
Luigi Bolondi is involved in the study of Cirrhosis that focuses on Chronic liver disease in particular.
His study in Gastroenterology concentrates on Liver disease and Liver function.
His Cancer research research is multidisciplinary, relying on both Cancer, Gene silencing and microRNA.
He most often published in these fields:
- Internal medicine (47.52%)
- Hepatocellular carcinoma (41.20%)
- Radiology (23.76%)
What were the highlights of his more recent work (between 2013-2021)?
- Hepatocellular carcinoma (41.20%)
- Internal medicine (47.52%)
- Gastroenterology (22.39%)
In recent papers he was focusing on the following fields of study:
Luigi Bolondi mostly deals with Hepatocellular carcinoma, Internal medicine, Gastroenterology, Oncology and Sorafenib.
The various areas that Luigi Bolondi examines in his Hepatocellular carcinoma study include Cancer, Carcinoma and microRNA.
His study on Cirrhosis, Hepatology, Disease and Liver function is often connected to In patient as part of broader study in Internal medicine.
The concepts of his Cirrhosis study are interwoven with issues in Magnetic resonance imaging, Radiology and Pathology.
His research integrates issues of Surgery, Survival analysis, Hepatitis C and Liver transplantation in his study of Gastroenterology.
His Oncology research focuses on subjects like Cabozantinib, which are linked to Tyrosine kinase.
Between 2013 and 2021, his most popular works were:
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma (631 citations)
- Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals (526 citations)
- Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial (450 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Surgery
Luigi Bolondi mainly focuses on Hepatocellular carcinoma, Internal medicine, Sorafenib, Liver cancer and Oncology.
He interconnects Cancer, Cirrhosis, Carcinoma and Surgery in the investigation of issues within Hepatocellular carcinoma.
His work on Randomized controlled trial as part of general Surgery research is frequently linked to Series, bridging the gap between disciplines.
His studies examine the connections between Internal medicine and genetics, as well as such issues in Gastroenterology, with regards to Hepatitis C.
His Sorafenib study combines topics in areas such as Adverse effect and Pharmacology.
His Liver cancer study integrates concerns from other disciplines, such as Stage, Liver transplantation and Angiogenesis.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
